Farmaceutica Remedia (BSE:RMAH) Research & Development: lei0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSE:RMAH Farmaceutica Remedia SA BSE:RMAH
58 GF Score
Price lei0.87
GF Value lei0.79
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Farmaceutica Remedia Research & Development?

Farmaceutica Remedia BSE:RMAH +0.23% 58 Research & Development is lei0.0 Mil as of Mar. 2026. GuruFocus rates BSE:RMAH with a GF Score™ of 58/100 and a GF Value™ of lei0.79 (Fairly Valued). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Farmaceutica Remedia's Research & Development for the three months ended in Mar. 2026 was lei0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was lei0.0 Mil.

Farmaceutica Remedia  (BSE:RMAH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Farmaceutica Remedia Research & Development Related Terms

Farmaceutica Remedia Research & Development Historical Data

* Premium members only.

The historical data trend for Farmaceutica Remedia's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farmaceutica Remedia Research & Development Chart

Farmaceutica Remedia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Farmaceutica Remedia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BSE:RMAH
58GF Score
Farmaceutica Remedia SA BSE:RMAH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Farmaceutica Remedia Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of lei0.0 Mil mean?
Farmaceutica Remedia (BSE:RMAH) has a Research & Development of lei0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Farmaceutica Remedia and its competitors.
Is Farmaceutica Remedia's Research & Development too high?
Farmaceutica Remedia's current Research & Development is lei0.0 Mil. Overall, Farmaceutica Remedia has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's Research & Development compare to MCK and CAH?
Farmaceutica Remedia's Research & Development of lei0.0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Farmaceutica Remedia and its competitors. Farmaceutica Remedia's current Research & Development is lei0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Based on GuruFocus' analysis, Farmaceutica Remedia (BSE:RMAH) is currently considered Fairly Valued. The stock's GF Value™ is lei0.79, compared to a current price of lei0.87 — trading 10.1% above its estimated fair value. The current Research & Development is lei0.0 Mil. Farmaceutica Remedia's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Farmaceutica Remedia (BSE:RMAH), the current Research & Development is lei0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Farmaceutica Remedia (BSE:RMAH) Overvalued in 2026?

Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued. The current stock price of lei0.87 is trading 10.1% above its estimated GF Value™ of lei0.79. GuruFocus considers Farmaceutica Remedia to be Fairly Valued.

Key valuation signals for BSE:RMAH:

  • Research & Development: lei0.0 Mil
  • GF Value™: lei0.79 vs. price of lei0.87 (10.1% above fair value)
  • GF Score™: 58/100 with 8 warning signs

No single metric tells the full story. See the BSE:RMAH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Farmaceutica Remedia Business Description

Address No. 2 Nicolae Balcescu Boulevard, Hunedoara County, Deva, ROU, 330040
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
58GF Score

Get the complete analysis for BSE:RMAH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei0.87
Price
lei0.79
GF Value